News

Eurostars-funded REPRINT consortium reaches milestones with evidence of complete tumor regression induced by dendritic cell reprogramming Schlieren, Switzerland | 11 April 2023  InSphero announces today, together

ZEISS Ventures invests in InSphero to further drive 3D cell culture research Oberkochen, Germany; Schlieren, Switzerland | 31 March 2023  ZEISS is investing in life

InSphero, leader in enabling pharma researchers to use predictive, human 3D cell-based disease models expands its NASH portfolio in collaboration with Vrije Universiteit Brussel (VUB)

New SAB member Nikolai Naoumov brings rich experience and expertise in liver disease, and pharma drug development, as well as a keen interest in 3D

InSphero, the leading biotech for the development of complex 3D research disease models, announced the appointment of Prof. Francisco Verdeguer as the new Vice President, Head of the Liver Discovery Group where he will be focusing on metabolic diseases, especially NASH and associated disease models.

InSphero to Offer Proprietary Microplates Engineered to Accelerate Development of Spheroid and Organoid Cultures Akura™ 96- and 384-well spheroid and organoid microplates and Akura™ Plus

InSphero and Pharmaceutical Companies Form Pre-Competitive Consortium to Advance Development of In Vitro Tools to Screen and Predict Drug-Induced Liver Injury (DILI) DILI is of

InSphero and Hamilton Announce Collaboration to Improve the Production and Handling of Spheroids Using Advanced Liquid Handling Technology Both partners have a proven track record

InSphero and Erasmus Medical Center Cancer Researcher Receive Grant to Develop Human In Vitro Model of Metastasis using the Akura™ Flow Technology Platform Schlieren, Switzerland